Biological-Age Tests: The Case for Repeatability and Real Outcomes

On October 12, 2026, MedTech Spectrum published an interview with Longevitix co-founders Effie Arditi and Dr Neil Panchal about biological-age testing and preventive healthcare. Arditi is the company’s CEO, and Panchal is its chief medical officer.

What is the central argument about healthy aging?

Panchal says a patient-facing test should reproduce its results, predict health outcomes and change after an intervention in a way that tracks changes in those outcomes. His argument places health and function at the center of biological-age testing rather than treating a lower score as the goal. For longevity medicine, that means evaluating whether a measurement helps explain or anticipate outcomes that matter to healthy lifespan. He describes these as the conditions he wants from a clinical test, not as an already established standard for the field.

What kind of evidence is being discussed?

Evidence setting: This is practitioner commentary about human testing, not a new study conducted in humans, in animal models or in vitro.

The interview combines the co-founders’ clinical and operational priorities with descriptions of earlier research. Its contribution is an account of what they believe biological-age testing needs before it earns a stronger role in care. Understanding that argument requires separating repeat measurement from prediction and intervention assessment.

Why does repeating the same measurement matter?

The interview cites a 2022 Nature Aging study reporting that technical noise produced deviations of up to nine years between replicate measurements of the same sample across six prominent clocks. It also reports that a principal-component method brought most replicates within 1.5 years. Both findings concern agreement between repeat measurements.

That comparison makes reliability a concrete part of the discussion. In the interview’s account, changing the analytical method improved agreement between repeats. The relevant question is therefore not simply whether a test returns an age in years. It is also how consistently the method produces its result when the underlying sample is repeated.

Panchal places that question at the beginning of his criteria for patient-facing tests. A result intended for monitoring needs an explanation of its repeatability so that later measurements have an interpretable starting point.

Why separate prediction from intervention response?

Panchal characterizes epigenetic clocks as stronger on outcome prediction than on reproducibility and intervention responsiveness. Predictive performance asks whether a result relates to what happens later. Intervention responsiveness asks whether a change after an intervention tracks a change in those later outcomes. His assessment treats these as separate evidence questions.

He argues that clinical validation should be anchored to hard outcomes. His examples include cardiovascular events, dementia, disability and death. These outcomes give the discussion a clearer target than the direction of a clock score alone.

For readers assessing claims about a test, the distinction helps organize the evidence. A claim about predicting risk should be evaluated as a prediction claim. A claim about demonstrating an intervention’s benefit requires evidence connecting the intervention-related measurement change to outcomes. This is the broader issue behind separating an age association from clinical proof.

What would more transparent reporting include?

Panchal calls for reports to identify the clock and platform used and to provide an error range or confidence interval. He also proposes shared reference materials and inter-laboratory proficiency testing. Arditi identifies reporting standards and cross-laboratory calibration as priorities.

These proposals address different parts of the measurement process. Naming the method identifies what generated the result. Reporting uncertainty gives the number context. Calibration and proficiency testing would address consistency between laboratories rather than leaving the discussion at the level of an individual report.

The interview also describes a Biomarkers of Aging Consortium framework published in Nature Medicine. According to its account, the framework calls for benchmarking alongside open data and open-source clock formulas. These priorities place transparency around the model itself alongside transparency around the result given to a patient.

For someone comparing test reports, this shifts attention from the prominence of the final number to the information supporting it. The method and its measurement performance become part of the result’s meaning rather than optional technical detail.

How could clinical follow-up strengthen the evidence?

Arditi proposes pragmatic trials and registries that pool outcomes across clinics. Her priorities connect laboratory standardization with evidence collected during clinical follow-up. In that approach, a clock’s performance would be evaluated alongside what happens to people rather than through repeated scores alone.

She also identifies an accepted surrogate endpoint as a potential turning point. Panchal argues that prevention trials could potentially be shorter if a biomarker’s change were accepted as predictive of hard outcomes. This is a conditional research prospect in the interview.

The proposed pathway therefore has distinct tasks: make measurements more dependable and connect their changes to meaningful outcomes. Progress on the measurement task would provide a clearer foundation for investigating the outcome task. Keeping those tasks separate makes it easier to understand what a particular validation effort is designed to establish.

What limits the conclusions readers should draw?

• The main source is practitioner commentary. The interview presents the views of Longevitix’s co-founders rather than an independent clinical trial. Panchal’s ranking of clock strengths is his clinical assessment.
• The cited reliability study is described indirectly. The interview does not provide its sample size or replicate count. It also does not identify the six clocks, so those details should not be inferred from this account.
• The numerical findings need their original qualifiers. The nine-year deviation is an upper-end result rather than a typical error estimate. The 1.5-year figure applies to most replicates using the principal-component method, not every repeat measurement.
• Different clocks need not agree for the same reason. Panchal says clocks can measure different dimensions of aging. Disagreement between different clocks is therefore distinct from repeatability problems within one clock.
• Repeatability does not establish clinical benefit. The 2026 review Geriatric Regenerative Medicine: Mechanisms, Strategies, and Clinical Translation cautions that biological-age measures have not yet been validated as substitutes for clinical benefit. Improving agreement between repeated measurements does not settle that question.
• The interview supplies no universal change threshold. Panchal says he would not use a two-year change for monitoring until reproducibility is routine. That is his stated position rather than a validated cutoff for interpreting every test.
• The proposed infrastructure is not evidence of implementation. Calls for calibration and reporting standards do not establish that those practices are already universal. Nor does the interview establish that every commercial report omits uncertainty information.
• The qualifying outcomes remain unsettled. Panchal says the field lacks agreement on which outcomes a clock must predict to merit a role in clinical decisions. His examples identify important targets without resolving that choice.

How should readers approach a test report?

The practical starting point is to ask which clock and platform generated the result. Follow that with questions about repeatability and the uncertainty attached to the measurement. These questions follow directly from the interviewees’ reporting priorities and provide a more useful basis for comparison than the score alone. AgeAmaze’s guide to comparing the evidence behind testing services provides a related framework.

Next, identify the kind of claim being made. Is the provider describing an association with future outcomes or arguing that a changed result demonstrates an intervention’s benefit? Ask for evidence that addresses the particular claim rather than treating all forms of validation as interchangeable.

Personal decisions belong in a discussion with a qualified clinician who can consider the result alongside other health information. Panchal says he gives more weight to trends in fitness, ApoB and HbA1c than to a single biological-age value. That is his clinical perspective rather than a universal monitoring protocol. The useful takeaway is to keep a clock result in context rather than make it the sole basis for action.

What research should come next?

The next step is prospective research that establishes repeatability and follows intervention-related clock changes alongside clinical and functional outcomes to test whether the measurements meaningfully track healthier lives.

How AgeAmaze helps

After biological-age testing comes the question of whether validation evidence justifies a clinical claim, and AgeAmaze helps readers understand that evidence through accessible longevity reporting. Overstated claims about biological age and emerging interventions can blur the distinction between a changing measurement and a demonstrated benefit; the publication explains the science and its uncertainty for adults seeking a grounded interpretation.

Read the research

Sources

1. Longevity Medicine Must Move Beyond Hype to Evidence-Based ...
2. Geriatric Regenerative Medicine: Mechanisms, Strategies, and Clinical Translation